Regentis Biomaterials (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process

At a glance

Company: Regentis Biomaterials
Ticker: NYSE American: RGNT
Announcement: Regulatory
Location: Europe

Key figures

Production yield increase: approximately 400%
Output from the same manufacturing volume: five times more product
Procedure duration: 10-minute
U.S. cartilage repair market value: approximately $3 billion
Annual U.S. cartilage knee repair cases addressed: approximately 470,000 cases

Products and programs

GelrinC
Gelrin platform technology

Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.

GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.

To view the full press release, visit https://ibn.fm/Ths4h

About Regentis Biomaterials

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

Regentis Biomaterials says a European Notified Body has cleared it to make GelrinC with a newer manufacturing method that does not use solvents. The company said the change supports the product’s planned European launch and is expected to increase yield by about 400%, or provide five times as much product from the same production volume. It also cited improved efficiency, scalability, and workplace and environmental safety. GelrinC already has CE Mark approval in Europe; it is a cell-free hydrogel implant intended to support cartilage regeneration in a minimally invasive procedure lasting 10 minutes. Regentis says clinical testing confirmed product consistency and performance. The company plans to support commercialization through European centers, surgeon training and institutional collaborations. The release also identifies a U.S. cartilage repair market valued at approximately $3 billion.

Key takeaways

Regentis received European Notified Body approval to manufacture GelrinC using a solvent-free process.
The company says the process raises production yield by approximately 400%, providing five times more product from the same volume.
GelrinC already holds CE Mark approval in Europe and is intended for minimally invasive cartilage repair.
Planned European commercialization support includes centers of excellence, surgeon training and collaborations with orthopedic institutions.

SEC filings

Earlier from Regentis Biomaterials

Back to News Center